Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of RO4917838 for predominant persistent negative symptoms of schizophrenia
2010-020467-21Phase 3Terminated
- Sponsor
- Roche
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing RO4917838 plus background antipsychotic treatment with Placebo plus background antipsychotic treatment (2 arms). Primary endpoint: Change in PANSS negative symptom factor score. Started Sep 2010; status: terminated.
02
Drugs
bitopertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2010-020467-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020467-21.